Assessment of Direct Cost of Care and Glycaemic Control among Diabetes Type 2 Patients in Two Mission Hospital Clinics in Kenya

View/ Open
Date
2024-09-21Author
WANYONYI, Kefa LAKASIA
BOR, Wesley
OPARE-ADO, Paul
Metadata
Show full item recordAbstract
Non communicable diseases are fast becoming the leading cause of mortality and morbidity
worldwide. It is estimated that 463 million people were living with diabetes in 2019. This number
is estimated to increase by two folds by 2045. Diabetes mellitus, being a chronic disease, needs
frequent hospital visits and follow up by clinicians. These contacts mean costs to the patient. The
increase in cost limits the hospital visits, medications purchase and laboratory investigations which
leads to poor management and prognosis. This study objective was to assess the direct cost of care
and glycaemic control of diabetes mellitus type 2 patients attending diabetes clinics in two mission
hospitals in Kenya. We used a cross-sectional study design was employed for this study. A
Kirkwood formula was used to determine the sample size for this study at 384 participants.
Random sampling technique was used to obtain the study subjects. A structured cost of care
questionnaire having questions on direct medical and non-medical costs was used to collect data.
Obtained data was analyzed using Microsoft excel and SPSS. Descriptive statistics entailed
Frequency counts, mean median and percentages interquartile range while inferential statistics
employed were- correlational and regression analysis. Most participants were aged over 60 with
21.6% being over 80 years. Mean total direct costs per visit was Kshs. 9,496.90 ± Kshs. 4,631.53
with drugs accounting for the larger proportion. Mean HbA1c and RBS values were established at
9.231% ± 2.4920% and 10.075 mmol/l ± 4.6503 mmol/l respectively. The direct cost of care of
T2DM is still relatively high with a wide variation yet the levels of glycemic control are yet to be
fully achieved in a larger proportion of diabetic type 2 patients